Drug firm Dr Reddy's Laboratories on Thursday said it has launched generic Naloxone Hydrochloride injection, indicated for complete or partial reversal of opioid depression, in the US market.
The company has launched Naloxone Hydrochloride injection USP, 2 mg/2 mL (1 mg/mL) single-dose prefilled syringe after the approval from the United States Food and Drug Administration (USFDA), Dr Reddy's said in a statement.
The product is a generic version of ADAPT Pharma Operations Ltd's Narcan injection, it added.
"We are pleased to bring our second product to market that has been designated as a Competitive Generic Therapy (CGT) by the USFDA," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said.
With a CGT designation, the company has 180-day CGT exclusivity to market this product, he added.
According to IQVIA Health data, Naloxone Hydrochloride injection USP, 2 mg/2 mL (1 mg/mL) had US sales of around USD 31 million (about Rs 230 crore) moving annual total for the most recent twelve months ended in January 2020.
Shares of Dr Reddy's Laboratories on Thursday closed 1.69 per cent lower at Rs 2,622.75 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app